IDXX vs VET: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

IDXX is the larger of the two ($54.34B market cap): the incumbent the market prices for continued execution (40.85x forward earnings, beta 1.54). VET is the smaller challenger ($1.54B), cheaper on forward earnings (6.85x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

IDXX vs VET: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricIDXXVETWhat it tells you
Market cap$54.34B$1.54BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E40.856.85Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.540.73Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range70% of range35% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book29.071.05How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: VET is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how IDXX and VET affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IDXX and VET share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IDXX and VET exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does IDEXX Laboratories, Inc. (IDXX) do?

IDEXX Laboratories (NASDAQ: IDXX) sells diagnostics to veterinarians. Its Companion Animal Group, roughly ~92% of revenue, places in clinic analyzers (Catalyst, ProCyte, SediVue and the newer inVue Dx) into practices and then sells the consumables those instruments burn through, while a global reference laboratory network runs the panels clinics send out. Practice management software and digital imaging (ezyVet, Cornerstone, ImageVue) sit alongside the diagnostics and pull more testing through the same customers. Two smaller segments round out the business: Water, which tests drinking water for coliform bacteria, and Livestock, Poultry and Dairy. The company is headquartered in Westbrook, Maine, employs about ~11,000 people, and sells into more than 175 countries.

Full IDXX guide

What does Vermilion Energy (VET) do?

Vermilion Energy Inc. is an international exploration and production company headquartered in Calgary, listed on both the Toronto Stock Exchange and the New York Stock Exchange under VET, and reporting in Canadian dollars. It earns its revenue by producing and selling natural gas, crude oil and natural gas liquids. In Canada, its anchor is the Alberta Deep Basin and Montney, a position that roughly doubled in scale with the ~C$1.075 billion purchase of privately held Westbrick Energy, which closed on February 26, 2025. In Europe, it produces gas in Germany, the Netherlands and Ireland (through the Corrib field), plus oil in France, and it also holds the Wandoo oil field offshore Australia. Production averaged 125,789 boe/d in the second quarter of 2026, about 71% natural gas.

Full VET guide

IDXX vs VET: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • IDXX drivers: The CAG Diagnostics recurring annuity; inVue Dx and the premium installed base.
  • VET drivers: European gas premium; Canadian Deep Basin scale.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. For VET, vermilion's cash flow is highly sensitive to European gas and Brent oil prices.

IDXX or VET: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IDXX if you believe its drivers more; VET if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IDXX and VET guides.

IDXX vs VET: the full fundamentals

IDXX. At roughly ~$564 a share and a market cap near ~$44.5B, IDEXX trades at about ~40x trailing earnings and ~34x the ~$16.73 analysts expect for 2027, and it pays no dividend. That is still a premium to the broader medical device group, though well below the multiples of 45x and above the stock carried through much of the past five years; the shares are down ~16% in 2026 and sit between a 52 week low of ~$501 and a high of ~$770. The twelve analysts Yahoo Finance tracks carry a mean target near ~$701, though JPMorgan trimmed its target to $750 from $775 on October 16.

VET. Because trailing GAAP earnings are negative after writedowns and hedge marks, investors usually value Vermilion on fund flows and free cash flow rather than on a trailing P/E. First-half 2026 fund flows were C$3.04 per share, which annualizes to about C$6 per share against a Toronto price of roughly C$18.50. On forward estimates, the P/E is about 10. The C$0.135 quarterly dividend implies a yield of roughly ~3%. Third-quarter 2026 results are expected in late October or early November 2026, and will reflect planned maintenance downtime.

Headline figures (approximate, October 2026): IDXX shows revenue (ttm) ~$4.55B; Q2 2026 revenue up ~9.7% year over year, cag diagnostics recurring revenue (q2 2026) ~$975M, up ~11%, about ~80% of total revenue, margins (ttm) Gross ~62.5%, operating ~35.0%, net ~25.0%, net income and eps (ttm) ~$1.14B net income, ~$14.07 EPS; Q2 EPS ~$4.27 vs ~$3.93 expected; VET shows share price (nyse, oct 16, 2026 close) ~US$13.20, market cap ~US$2.0 billion, q2 2026 sales (continuing operations) ~C$554 million, eps (ttm) ~-US$2.05 (impairment-driven loss); P/E not meaningful.

The bottom line: IDXX vs VET

IDXX and VET are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IDXX and VET exposure against your real portfolio. It is not an investment adviser.

Wondering how IDXX or VET fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about IDEXX Laboratories, Inc.

Ask Walnut's AI anything about IDXX and see how it fits what you own.

FAQ

What is the difference between IDXX and VET?

+

IDEXX Laboratories (NASDAQ: IDXX) sells diagnostics to veterinarians. Vermilion Energy Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is IDXX or VET the better stock?

+

Neither is universally better. IDXX is the larger incumbent; VET is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, IDXX or VET?

+

On forward P/E (as of November 2026), IDXX trades at 40.85x and VET at 6.85x, so VET is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both IDXX and VET?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of IDXX vs VET?

+

IDXX: Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. Wellness visits, down more than ~3%, sit at the discretionary end of veterinary spending and track consumer pressure and muted puppy adoption directly. Competition is intensifying from Mars owned Antech, which absorbed Heska and can now bundle in clinic analyzers with a national laboratory network the way IDEXX does, and from Zoetis in point of care instruments. Roughly ~23% of revenue is non US, so currency both flattered first half reported growth and now costs an estimated ~$15 million against the full year outlook. Leverage is not the concern, at about ~$1.1 billion of debt against ~$197 million of cash and ~$1.6 billion of EBITDA, but the ~27% drawdown from the 52 week high is a reminder of how fast this multiple reprices when the volume narrative wobbles. VET: Vermilion's cash flow is highly sensitive to European gas and Brent oil prices. If new global LNG supply pushes TTF and NBP back toward historical levels, the premium that sets it apart from Canadian peers would shrink, and the company would look more like a typical Deep Basin producer. Canadian gas remains weak, with AECO averaging only ~C$1.51/mcf in Q2 2026. Europe carries its own political and fiscal risk: governments have imposed windfall taxes on energy producers before, and drilling permits in countries such as the Netherlands and Germany can be slow or contested. Reported earnings are volatile because of impairments (a ~C$372 million writedown on discontinued assets in Q2 2025) and swings in unrealized hedge values, which is why trailing EPS is negative. Net debt of ~C$1.22 billion is meaningful against a ~US$2.0 billion market cap. Production dips during maintenance (Q3 2026 guidance is 116,000 to 118,000 boe/d), and the stock has traded between roughly US$7.11 and US$14.82 over the past 52 weeks.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IDXX or VET; figures are approximate and dated (as of November 2026). Verify current data before investing.